Granted Patent
B2
US 10,093,627 · App. 15/661,143 · Granted Oct 9, 2018
Tetrahydroquinoline derivatives and their use as Epac inhibitors
Inventors:
Frank Lezoualc'h (Toulouse, FR); Rodolphe Fischmeister (Chatenay-Malabry, FR); Malik Bisserier (Toulouse, FR); Pascal Bouyssou (Orleans, FR); Jean-Paul Blondeau (Chatenay-Malabry, FR); Delphine Courilleau (Chatenay-Malabry, FR)
Assignees:
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PAUL SABATIER TOULOUSE III; UNIVERSITE PARIS-SUD; UNIVERSITE D'ORLEANS
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
Claims (1)
1. A composition, comprising a pharmaceutically acceptable carrier, and compound having the following formula:
Assignments (2)
MERGER
Recorded Aug 22, 2022
From: UNIVERSITE DE PARIS 11 - PARIS SUD (ALSO NAMED UNIVERSITÉ PARIS-SUD)
To: UNIVERSITE PARIS-SACLAY
Reel/Frame 060856/0245 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 27, 2017
From: LEZOUALC'H, FRANK; FISCHMEISTER, RODOLPHE; BISSERIER, MALIK; BOUYSSOU, PASCAL; BLONDEAU, JEAN-PAUL; COURILLEAU, DELPHINE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM); UNIVERSITE PAUL SABATIER TOULOUSE III; UNIVERSITE PARIS-SUD; UNIVERSITE D'ORLEANS
Reel/Frame 043115/0713 →
Priority Claims (1)
EP 12306201
· Oct 2, 2012
· regional
Continuity (2)
Continuation
14432768